Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Background: Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that was recently approved by the FDA for treatment of patients (pts) with relapsed/refractory marginal zone lymphoma (MZL) who have already received one or more anti-CD20 containing treatment regimens and require systemic ther...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.5250-5250
Hauptverfasser:	Weiner, David M., Robinson, Nathaniel D., Bair, Steven M., Ballard, Hatcher J., Hughes, Mitchell E., Dwivedy Nasta, Sunita, Landsburg, Daniel J., Barta, Stefan K., Chong, Elise A., Schuster, Stephen J., Svoboda, Jakub
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!